DK1397145T3 - Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser - Google Patents

Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser

Info

Publication number
DK1397145T3
DK1397145T3 DK02738138T DK02738138T DK1397145T3 DK 1397145 T3 DK1397145 T3 DK 1397145T3 DK 02738138 T DK02738138 T DK 02738138T DK 02738138 T DK02738138 T DK 02738138T DK 1397145 T3 DK1397145 T3 DK 1397145T3
Authority
DK
Denmark
Prior art keywords
cox
inhibitors
treat schizophrenia
tics
disorders
Prior art date
Application number
DK02738138T
Other languages
Danish (da)
English (en)
Inventor
Norbert Mueller
Original Assignee
Norbert Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129320A external-priority patent/DE10129320A1/de
Application filed by Norbert Mueller filed Critical Norbert Mueller
Application granted granted Critical
Publication of DK1397145T3 publication Critical patent/DK1397145T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02738138T 2001-06-19 2002-05-31 Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser DK1397145T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129320A DE10129320A1 (de) 2001-06-19 2001-06-19 Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US36490402P 2002-03-14 2002-03-14

Publications (1)

Publication Number Publication Date
DK1397145T3 true DK1397145T3 (da) 2007-01-02

Family

ID=26009543

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02738138T DK1397145T3 (da) 2001-06-19 2002-05-31 Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser
DK05024864.0T DK1627639T3 (da) 2001-06-19 2002-05-31 Anvendelse af COX-2-inhibitorer til behandling af affektive lidelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05024864.0T DK1627639T3 (da) 2001-06-19 2002-05-31 Anvendelse af COX-2-inhibitorer til behandling af affektive lidelser

Country Status (16)

Country Link
US (1) US20040204469A1 (ja)
EP (2) EP1397145B1 (ja)
JP (2) JP4205577B2 (ja)
AP (1) AP1512A (ja)
AT (2) ATE452642T1 (ja)
AU (1) AU2002312967A1 (ja)
CA (1) CA2448025C (ja)
CY (1) CY1109949T1 (ja)
DE (2) DE60234873D1 (ja)
DK (2) DK1397145T3 (ja)
EA (1) EA009780B1 (ja)
ES (2) ES2336682T3 (ja)
OA (1) OA12627A (ja)
PT (2) PT1397145E (ja)
SI (1) SI1627639T1 (ja)
WO (1) WO2002102297A2 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
CN101371843B (zh) * 2002-11-26 2012-09-26 艾利斯达医药品公司 洛沙平和阿莫沙平在制备治疗疼痛的药物中的应用
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
CA2526432A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
EP1687001A2 (en) * 2003-11-19 2006-08-09 Glaxo Group Limited Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
JP2007511569A (ja) * 2003-11-19 2007-05-10 グラクソ　グループ　リミテッド 鬱病性障害の治療用のシクロオキシゲナーゼ−２阻害剤の使用
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005084654A2 (en) * 2004-03-02 2005-09-15 Pharmacia Corporation Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
JP5144104B2 (ja) 2007-04-09 2013-02-13 ユニ・チャーム株式会社 伸縮性複合シート及びそれを用いた使い捨て着用物品
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
EP2340818A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of venlafaxine and celecoxib
EP2340819A1 (en) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising venlafaxine and celecoxib in the treatment of pain
SG11202005016SA (en) 2017-12-05 2020-06-29 Sunovion Pharmaceuticals Inc Nonracemic mixtures and uses thereof
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579846A (en) * 1984-10-11 1986-04-01 Pfizer Inc. Antiinflammatory compositions and methods
WO1999025353A1 (en) * 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
EP1142889A1 (en) * 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazole derivatives as anti-inflammatory/analgesic agents
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor

Also Published As

Publication number Publication date
JP2008297308A (ja) 2008-12-11
EA009780B1 (ru) 2008-04-28
AP1512A (en) 2005-12-15
DE60214542D1 (de) 2006-10-19
WO2002102297A3 (en) 2003-05-01
OA12627A (en) 2006-06-13
US20040204469A1 (en) 2004-10-14
EP1397145B1 (en) 2006-09-06
JP4824727B2 (ja) 2011-11-30
CA2448025A1 (en) 2002-12-27
EP1627639A2 (en) 2006-02-22
EA200301291A1 (ru) 2004-06-24
SI1627639T1 (sl) 2010-04-30
CA2448025C (en) 2011-07-05
DE60214542T2 (de) 2006-12-21
CY1109949T1 (el) 2014-09-10
PT1397145E (pt) 2006-10-31
DK1627639T3 (da) 2010-04-26
AU2002312967A1 (en) 2003-01-02
PT1627639E (pt) 2010-03-01
EP1397145A2 (en) 2004-03-17
DE60234873D1 (de) 2010-02-04
EP1627639B1 (en) 2009-12-23
WO2002102297A2 (en) 2002-12-27
JP4205577B2 (ja) 2009-01-07
ES2336682T3 (es) 2010-04-15
ATE338557T1 (de) 2006-09-15
ATE452642T1 (de) 2010-01-15
JP2004534066A (ja) 2004-11-11
AP2003002934A0 (en) 2003-12-31
ES2271269T3 (es) 2007-04-16
EP1627639A3 (en) 2006-09-27

Similar Documents

Publication Publication Date Title
DK1397145T3 (da) Anvendelse af COX-2-inhibitorer til behandling af schizophrenia eller tics-lidelser
ATE370938T1 (de) Pro-pharmakon von cox-2-inhibitoren
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
LTPA2017004I1 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
EE200300361A (et) PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
DK1132570T3 (da) Sammensætninger til syrebehandling af borebrönde
ATE435901T1 (de) Verfahren zur kontrolle der rheologischen eigenschaften von viscoelastischen tensid- basierte bohrflüssigkeiten
DK1463506T3 (da) Substituerede quinazolin-derivater som inhibitorer af aurora-kinaser
DK1562589T3 (da) Diaminotriazoler der er nyttige som inhibitorer af proteinkinaser
ATE323072T1 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
DK1894564T3 (da) Anvendelse af en IBAT inhibitor til behandling eller profylakse af konstipation
DE602005014646D1 (de) Substituierte propenylpiperazinderivate als neue inhibitoren von histondeacetylase
DE60324166D1 (de) Dihydropyridinderivaten zur verwendung als inhibitoren der menschlichen neutrophilenelastase
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DE602004012448D1 (de) Morpholinylhaltige benzimidazole als inhibitoren der replikation von respiratory syncytial virus
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
ATE430726T1 (de) N-acylamino-benzyletherderivate als selektive inhibitoren der monoaminoxidase b
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
DK1503747T3 (da) Diclofenacbaseret sammensætning til topisk behandling af sygdomme
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer